Aradigm Corporation (NASDAQ:ARDM) released its quarterly earnings results on Thursday. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05, Bloomberg Earnings reports. Aradigm Corporation had a negative return on equity of 665.03% and a negative net margin of 118.37%. The firm had revenue of $2.73 million during the quarter.

Aradigm Corporation (NASDAQ:ARDM) traded down $0.48 during trading hours on Friday, reaching $3.61. The company’s stock had a trading volume of 177,451 shares, compared to its average volume of 237,786. The company has a debt-to-equity ratio of -2.34, a quick ratio of 2.52 and a current ratio of 2.52.

TRADEMARK VIOLATION NOTICE: “Aradigm Corporation (ARDM) Announces Earnings Results” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at

A number of equities analysts have weighed in on the company. Zacks Investment Research downgraded Aradigm Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $10.00 price target (up previously from $7.50) on shares of Aradigm Corporation in a research report on Monday, September 25th.

Aradigm Corporation Company Profile

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Earnings History for Aradigm Corporation (NASDAQ:ARDM)

Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with's FREE daily email newsletter.